Gilead Sciences/$GILD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Ticker
- $GILD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17,000
- Headquarters
- Foster City, United States
- Website
- www.gilead.com
Gilead Sciences Metrics
BasicAdvanced
$194B
-
-$2.61
0.34
$3.25
2.10%
Price and volume
Market cap
$194B
Beta
0.34
52-week high
$160.51
52-week low
$114.02
Average daily volume
5.9M
Dividend rate
$3.25
Financial strength
Current ratio
1.265
Quick ratio
0.902
Long term debt to equity
2.029
Total debt to equity
2.235
Interest coverage (TTM)
12.51%
Profitability
EBITDA (TTM)
15,240
Gross margin (TTM)
79.60%
Net profit margin (TTM)
-10.64%
Operating margin (TTM)
38.88%
Effective tax rate (TTM)
-65.73%
Revenue per employee (TTM)
$1,790,000
Management effectiveness
Return on assets (TTM)
14.09%
Return on equity (TTM)
-20.68%
Valuation
Price to revenue (TTM)
6.372
Price to book
16.39
Price to tangible book (TTM)
-18.43
Price to free cash flow (TTM)
14.994
Free cash flow yield (TTM)
6.67%
Free cash flow per share (TTM)
10.417
Dividend yield (TTM)
2.08%
Forward dividend yield
2.10%
Growth
Revenue change (TTM)
5.52%
Earnings per share change (TTM)
-152.18%
3-year revenue growth (CAGR)
3.61%
10-year revenue growth (CAGR)
-0.61%
3-year earnings per share growth (CAGR)
-15.60%
10-year earnings per share growth (CAGR)
-13.69%
3-year dividend per share growth (CAGR)
2.85%
10-year dividend per share growth (CAGR)
6.23%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Analyst projections of the future price of Gilead Sciences stock.
Bulls say / Bears say
Second-quarter base-business revenue rose 10% and HIV sales grew 12%; quarterly PrEP sales more than doubled year on year to over $1 billion. That gives Gilead a strong growth engine beyond its established treatment franchise. (Gilead Sciences)
Gilead and Merck reported that two Phase 3 trials of their once-weekly oral HIV treatment met their main efficacy goals and showed no new safety concerns. If approved, the regimen could add a new treatment option and support future growth. (Gilead Sciences)
Trodelvy gained US approval for first-line triple-negative breast cancer, expanding its addressable market, while second-quarter sales rose 26% to $457 million. This gives Gilead a growing oncology product alongside its much larger HIV business. (Gilead Sciences, Endpoints News)
Cell-therapy sales fell 14% in the second quarter, with Yescarta down 12% as competition increased. That pressure is weighing on an important part of Gilead’s effort to build growth beyond HIV. (Gilead Sciences)
Gilead and Merck stopped the Phase 3 EVOKE-03 trial of Trodelvy in lung cancer after the review found no basis to continue. The setback limits Trodelvy’s potential beyond breast cancer and shows that pipeline expansion remains uncertain. (Gilead Sciences)
Gilead recorded $11.2 billion in acquired research-and-development charges in the second quarter, largely tied to recent acquisitions, and reported a substantial GAAP loss. The spending raises the stakes for Gilead to turn its newly acquired pipeline assets into successful medicines. (Stock Titan)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Gilead Sciences News
AllArticlesVideos
Funds containing Gilead Sciences
AllUSDGBPEUR
Fund name | Fund size | $GILD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 8.74% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 8.74% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 3.04% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 3.00% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 2.65% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.